Interní Med. 2012; 14(12): 461-464

New insights in pathogenesis and treatment of iron deficiency nad iron overload

doc.MUDr.Jaroslav Čermák, CSc.
Ústav hematologie a krevní transfuze, Praha

New mechanisms involved in pathogenesis of iron deficiency nad iron overload has been reported within past twenty years. A regulation

of intracellular iron level caused by control of synthesis of proteins involved in iron metabolism by labile free cytoplasmic iron via

binding of IRP on mRNA IRE has been described. Hepcidin represents an essential regulator of iron output from cells to circulation.

Substitution of iron still represents the main treatment approach to patients with iron deficiency. A concomitant administration od iron

in patients with anemia of chronic disease treated with erythropoetin has been recently discussed. New oral iron chelators represent

a significant improvement in the treatment of iron overload and their administration enabled a switch from the treatment to effective

prophylaxis of iron overload.

Keywords: iron overload, iron deficiency, pathogenesis, treatment

Published: January 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čermák J. New insights in pathogenesis and treatment of iron deficiency nad iron overload. Interní Med. 2012;14(12):461-464.
Download citation

References

  1. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nature Chemical Biology 2006; 2: 406-414. Go to original source... Go to PubMed...
  2. Roy CN, Enns CA. Iron homeostasis: new tales from the krypt. Blood. 2000; 96: 4020-4027. Go to original source...
  3. Eisenstein RS, Blemings KP. Iron Regulatory Proteins, Iron Responsive Elements and Iron Homeostasis. J. Nutr. 1998; 128: 2295-2298. Go to original source... Go to PubMed...
  4. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-788. Go to original source... Go to PubMed...
  5. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 2005; 106: 3710-3717. Go to original source... Go to PubMed...
  6. Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 2005; 290: G199-G203. Go to original source... Go to PubMed...
  7. Cabantchik ZI, Breuer W, Zanninelli G, Cianculli P. LPI-labile plasma iron in iron overload. Best Practice & Res Clin Haematol 2005; 18: 277-287. Go to original source... Go to PubMed...
  8. Lankhorst CE, Wish JB. Anemia in renal disease: Diagnosis and management. Blood Reviews 2010; 24: 30-47. Go to original source... Go to PubMed...
  9. Davis SL, Littlewood TJ. The investigation and treatment of secondary anaemia. Blood Reviews 2012; 26: 65-71. Go to original source... Go to PubMed...
  10. Čermák J, Gregora E, Lachmanová J, Brabec V. Sledování zásob železa u nemocných s chronickým selháním ledvin léčených rekombinantním lidským erytropoetinem. Vnitř. Lék. 1994; 40: 174-178.
  11. Hershko C, Link G, Konijn AM, Cabantchik ZI. Iron chelation therapy. Curr Haematol Rep 2005; 4: 110-116.
  12. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339: 417-423. Go to original source... Go to PubMed...
  13. List AF, Baer MR, Steensma D, et al. Iron chelation with deferasirox (Exjade(R)) improves iron burden in patients with myelodysplastic syndromes (MDS). Blood 2008; 112: 236. Go to original source...
  14. Gattermann N, Finelli C, Della Porta M et al.: Hematologic responses in myelodysplastic syndromes (MDS) patients treated with deferasirox. An EPIC post-hoc analysis using international working group (IWG) 2006 criteria. Blood 2011; 118: 661. Go to original source...
  15. Sanz G, Nomdedeu B, Sach, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008; 112: 238. Go to original source...
  16. Gattermann N: Overview of guidelines on iron chelation in patients with myelodysplastic syndrome. Int J Hematol 2008; 88: 24-29. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.